Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q2 2019 · 10-Q
Revenue$75.04M$75.04M+2.7% vs Q2 2018 Net Income-$4.71M-$4.71MN/M vs Q2 2018 EPS Diluted-$0.14-$0.14N/M vs Q2 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$14,627,000−73.7% Free Cash Flowderived$13,752,000−75.0% Margins · derivedGross margin35.2%
Operating margin-6.7%+3.3 pt vs Q2 2018
Net margin-6.3%+11.6 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 7, 2019 · 38 d after period end